טוען...
Harms of off‐label erythropoiesis‐stimulating agents for critically ill people
BACKGROUND: Anaemia is a common problem experienced by critically‐ill people. Treatment with erythropoiesis‐stimulating agents (ESAs) has been used as a pharmacologic strategy when the blunted response of endogenous erythropoietin has been reported in critically‐ill people. The use of ESAs becomes m...
שמור ב:
| הוצא לאור ב: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Ltd
2017
|
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6373621/ https://ncbi.nlm.nih.gov/pubmed/28841235 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010969.pub2 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|